Drug Trial Radar · NCT05843578
STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
103
Actual
Start
Aug 1, 2023
Primary completion
Jun 20, 2026
Study completion Jun 20, 2026
Sponsor
- Lead sponsor
- Agomab Spain S.L.U.Industry
- Sponsor type
- Industry
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Many patients with Crohn's disease develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals. Because of these symptoms, patients often require bowel resection surgery. The objective of this clinical trial is to evaluate the safety, pharmacokinetics, and pharmacodynamics of AGMB-129 (Ontunisertib) in patients with Crohn's disease and symptomatic strictures, and whether it can have a beneficial effect on intestinal strictures. The participants will be in the Part A for a duration of up to 19 weeks including a 5 week screening period, a 12-week double-blind, placebo-controlled treatment period, and 2 week safety follow up period. Participants who continue to Part B can receive treatment for up to an additional 48 weeks, with a safety follow-up visit 2 weeks after the last dose of treatment.
Conditions
- Fibrostenotic Crohn's Disease
Interventions
AGMB-129Drug
Oral capsule
PlaceboDrug
Matching oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (Part A and B)Time frame: From Screening to Week 48
- Number of participants with abnormal clinical laboratory values (Part A and B)Time frame: From Screening to Week 48
- Number of participants with abnormal ECG parameters (Part A and B)Time frame: From Screening to Week 48
- Number of participants with abnormal vital signs (Part A and B)Time frame: From Screening to Week 48
- Number of participants with abnormal physical exams (Part A and B)Time frame: From Screening to Week 48
- Number of participants with abnormal 2D-echocardiography (Part A and B)Time frame: From Screening to Week 48
Locations
52 sites in 8 countries. Site status is shown where the registry gives one.
Medical Research Center of Connecticut, LLC
Hamden, Connecticut
University of Miami
Miami, Florida
Digestive and Liver Center of Florida
Orlando, Florida
Gastroenterology Health Partners
New Albany, Indiana
Gastroenterology Health Partners
Louisville, Kentucky
Louisiana Research Center
Shreveport, Louisiana
University of Michigan
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Cleveland Clinic
Cleveland, Ohio
Gastro One
Cordova, Tennessee
Medical University of Graz
Graz, Austria
Gemeinnutzige Salzburger Landeskliniken Betriebsgesellschaft mbH (Landeskrankenhaus Salzburg/Regional Hospital Salzburg)
Salzburg, Austria
Medical University Of Vienna (AKH Wien)
Vienna, Austria
Hospital Landstrasse, Department of Internal Medicine IV
Vienna, Austria
University of Calgary
Calgary, Canada
Gastroenterology and Internal Medicine Research Institute (GIRI)
Edmonton, Canada
South Edmonton Gastroenterology Research Clinic
Edmonton, Canada
Nova Scotia Health Authority
Halifax, Canada
TIDHI Innovation Inc.
North York, Canada
Ottawa Hospital Research Institute
Ottawa, Canada
(G.I.R.I) GI Research Institute
Vancouver, Canada
Aarhus University Hospital, Department of Hepatology and Gastroenterology
Aarhus, Denmark
Bispebjerg Hospital
Copenhagen, Denmark
Rigshospitalet - University Hospital Copenhagen
Copenhagen, Denmark
Herlev Hospital (University of Copenhagen)
Herlev, Denmark
Odense University Hospital
Odense, Denmark
Charite Universitatsmedizin Berlin KöR Campus Benjamin Franklin Medizinische
Berlin, Germany
Servicegesellschaft Krankenhaus Waldfriede mbH Krankenhaus Waldfriede e.V Akademisches Lehrkrankenhaus der Charite
Berlin, Germany
BSF Studiengesellschaft UG (Unternehmergesellschaft, haftungsbeschränkt)
Halle, Germany
Universitatsklinikum Ulm AöR (University of Ulm)
Ulm, Germany
University Polyclinic Hospital "G. Martino"
Messina, Italy
Humanitas Research Hospital IRCCS Istituto Clinico Humanitas
Milan, Italy
Hospital San Raffaele
Milan, Italy
Azienda Ospedaliero Universitaria di Modena - Struttura Complessa di Gastroenterologia
Modena, Italy
Sacred Heart Don Calabria
Negrar, Italy
Azienda Ospedaliera San Camillo Forlanini
Rome, Italy
University Polyclinic Foundation "Agostino Gemelli"
Rome, Italy
Specialist Gastrology Centre GASTROMED
Bialystok, Poland
Vita Longa Sp. z.o.o.
Katowice, Poland
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.